Minghui Pharmaceutical to Present the Phase I/II Study of MHB088C (B7-H3 ADC) for the Treatment of Patients with Recurrent or Metastatic Solid Tumors in Late-breaking Oral Presentation at the 2024 ASCO Annual Meeting ...Middle East

SHANGHAI, May 8, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company focused on autoimmune diseases and oncology, will feature Dr. Lin Shen from Beijing Cancer Hospital at the upcoming ASCO Annual Meeting in Chicago. Dr. Shen will present the...

Hence then, the article about minghui pharmaceutical to present the phase i ii study of mhb088c b7 h3 adc for the treatment of patients with recurrent or metastatic solid tumors in late breaking oral presentation at the 2024 asco annual meeting was published today ( Wednesday 08/05/2024 - 01:24 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Minghui Pharmaceutical to Present the Phase I/II Study of MHB088C (B7-H3 ADC) for the Treatment of Patients with Recurrent or Metastatic Solid Tumors in Late-breaking Oral Presentation at the 2024 ASCO Annual Meeting )

Also on site :

• ‘We can insure the ship, but we cannot insure a human life.’
• Israel’s military posted two images of Ali Choeib in what it said was a Hezbollah uniform. One was fake.
• Nelly Furtado Is More Gorgeous Than Ever 5 Months After Sharing She Quit Performing Due to Body Shaming